Table1_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.DOCX حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image9_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image12_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image4_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image7_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image6_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Table2_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.DOCX حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image11_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image13_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image14_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image1_Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis.TIF حسب Runzhi Huang (7428713)

"…Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma.…"

Image5_LeishIF3d is a non-canonical cap-binding protein in Leishmania.TIF حسب Priyanka Bose (7110071)

"…We describe a non-canonical cap-binding activity of LeishIF3d and examine its potential role in driving translation. …"

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases IgG and IgG1 breadth. حسب LaTonya D. Williams (3140490)

50 WT 5′ and 3′ terminal nts of the S1 gene are sufficient to package a non-MRV gene into infectious virions. حسب Debarpan Dhar (724473)

Decreasing HIV viral loads across subdistricts in KwaZulu-Natal province, South Africa, between 2018 and 2022. حسب Lilishia Gounder (15240167)

الموضوعات:

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. حسب Florencia Sabbione (4862455)

Knockdown of FZD10 results in a decrease in cell proliferation in the neural tube. حسب Abdulmajeed Fahad Alrefaei (8968607)

"…<p>(A, B, D, E) Cross sections of neural tube stained with DAPI and phosphor-histone H3 (green), showing the electroporated (RFP) and non-electroporated sides. …"

Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx حسب Bin Liu (5899)

"…The 5-year CSS rates were 95.0% and 77.0% in patients of waiting time within 3 months and over 3 months, respectively. …"

Spatial training decreases the association between Ndfip1 and Nedd4 and decreases endogenous Beclin 1 ubiquitination in the hippocampus. حسب Wei-Lun Hsu (1756123)

"…<p><b>(A)</b> The CA1 tissue lysates from non-trained and trained rats were immunoprecipitated with IgG and immunoblotted with anti-Nedd4 and anti-Ndfip1 antibodies to serve as the control group. …"